Evidence map›Paper›PMID 37059591›Full record

ArticleAging2023

Comprehensive analysis reveals TSEN54 as a robust prognosis biomarker and promising immune-related therapeutic target for hepatocellular carcinoma.

Bidong Fu, Minqin Zhou, Gelin Song, Hong Zeng, Yiyang Gong, Yike Jiang, Yun Ke, Da Huang, Hong Peng, Qing Li

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Bidong FuDepartment of Pathology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China.
Minqin ZhouSecond College of Clinical Medicine, Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China.
Gelin SongSecond College of Clinical Medicine, Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China.
Hong ZengSecond College of Clinical Medicine, Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China.
Yiyang GongSecond College of Clinical Medicine, Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China.
Yike JiangSecond College of Clinical Medicine, Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China.
Yun KeSecond College of Clinical Medicine, Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China.
Da HuangDepartment of Thyroid Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China.
Hong PengDepartment of Colorectal Surgery, 908th Hospital of Chinese People’s Liberation Army Joint, Nanchang, Jiangxi Province, People’s Republic of China.
Qing LiDepartment of Pathology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China.
Second Affiliated Hospital of Nanchang University · CNNanchang University · CNJiangxi Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma represents the most common primary malignancy of all liver cancer types and its prognosis is usually unsatisfactory. TSEN54 encodes a protein constituting a subunit of the tRNA splicing endonuclease heterotetramer. Previous researches concentrated on the contribution of TSEN54 in pontocerebellar hypoplasia, but no studies have yet reported its role in HCC.

methodsTIMER, HCCDB, GEPIA, HPA, UALCAN, MEXPRESS, SMART, TargetScan, RNAinter, miRNet, starBase, Kaplan-Meier Plotter, cBioPortal, LinkedOmics, GSEA, TISCH, TISIDB, GeneMANIA, PDB, GSCALite were applied in this research.

resultsWe identified the upregulation of TSEN54 expression in HCC and related it to multiple clinicopathological features. Hypomethylation of TSEN54 was closely associated with its high expression. HCC sufferers who held high TSEN54 expression typically had shorter survival expectations. Enrichment analysis showed the involvement of TSEN54 in the cell cycle and metabolic processes. Afterward, we observed that TSEN54 expression level had a positive relationship to the infiltration level of multiple immune cells and the expression of several chemokines. We additionally identified that TSEN54 was related to the expression level of several immune checkpoints and TSEN54 was linked to several m6A-related regulators.

conclusionsTSEN54 is a prognostic marker of HCC. TSEN54 could become a prospective candidate for HCC diagnosis and therapy.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsBiomarkersBiomarkers, TumorCell CycleCell DivisionEndoribonucleasesHumansPrognosisBiomarkersBiomarkers, TumorEndoribonucleasesTSEN54 protein, humanbiomarkerhepatocellular carcinomaimmune infiltrationm6A modificationTSEN54

Identifiers

PMID37059591
PMCPMC10120902
OpenAlexW4365503087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.